Other checkpoint molecules such as LAG-3, TIM-3, TIGIT, VISTA and B7-H3 and other TME molecules such as IDO have been demonstrated to be promising targets for melanoma and other advanced solid tumors in preclinical studies, granting their passage into clinical trials, although all of them are currently ongoing (Kwiatkowska et al., 2019; Qin et al., 2019). This evidence concerns the gene LAG3 and melanoma.